Cancer Stem Cell News Volume 10.34 | Sep 1 2021

    0
    38







    2021-09-01 | CSCN 10.34


    Cancer Stem Cell News by STEMCELL Technologies
    Vol. 10.34 – 1 September, 2021
    TOP STORY

    METTL14 Facilitates Global Genome Repair and Suppresses Skin Tumorigenesis

    Scientists showed that methyltransferase-like 14 (METTL14) , a critical component of the N6-methyladenosine (m6A) RNA methyltransferase complex, promoted global genome repair through regulating m6A mRNA methylation–mediated DDB2 translation and suppresses ultraviolet B radiation-induced skin tumorigenesis.
    [Proceedings of the National Academy of Sciences of the United States of America]

    Abstract
    Explore scientific events this September with the Science Events Calendar.
    PUBLICATIONSRanked by the impact factor of the journal

    TET3 Promotes AML Growth and Epigenetically Regulates Glucose Metabolism and Leukemic Stem Cell Associated Pathways

    Investigators reported that the epigenetic factor, Ten-Eleven Translocation 3 (TET3) dioxygenase was overexpressed in acute myeloid leukemia (AML) patients and functionally validated human leukemic stem cells, and was required for leukemic growth by virtue of its regulation of glucose metabolism in AML cells.
    [Leukemia]

    Abstract

    Transcriptional Control of Brain Tumor Stem Cells by a Carbohydrate Binding Protein

    The authors reported that the LGALS1 gene, encoding the carbohydrate binding protein, galectin1, is a key regulator of brain tumor stem cells and glioblastoma resistance to therapy.
    [Cell Reports]

    Full ArticlePress ReleaseGraphical Abstract

    Sunitinib Increases the Cancer Stem Cells and Vasculogenic Mimicry Formation via Modulating the lncRNA-ECVSR/ERβ/Hif2-α Signaling

    Researchers found that sunitinib could have adverse effects of promoting renal cell carcinoma (RCC) progression by increasing vascular mimicry formation of RCC cells.
    [Cancer Letters]

    Abstract

    Chronic Exposure to FGF2 Converts iPSCs into Cancer Stem Cells with an Enhanced Integrin/Focal Adhesion/PI3K/AKT Axis

    Scientists designed a meta-analysis to assess gene expression profiles in different breast cancer cell lines focusing on the secretory factors responsible for conversion.
    [Cancer Letters]

    Abstract

    Deep-Red/Near-Infrared Turn-On Fluorescence Probes for Aldehyde Dehydrogenase 1A1 in Cancer Stem Cells

    Investigators reported deep-red/near-infrared turn-on fluorescence probes, CS5-A and CS7-A, targeted to aldehyde dehydrogenase 1A1 as an intracellular CSC marker.
    [ACS Sensors]

    Abstract

    DAB2IP Destabilizes C-Myc to Impair the Growth and Self-Renewal of Colon Tumor-Repopulating Cells

    The authors reported that elevated c-Myc protein supported formation and growth of tumor-repopulating cell spheroids. The tumor suppressor DOC-2/DAB2 interactive protein suppressed c-Myc expression to inhibit tumor-repopulating cells expansion and self-renewal.
    [Cancer Science]

    Abstract

    Long Noncoding RNA LINC00261 Upregulates ITIH5 to Impair Tumorigenic Ability of Pancreatic Cancer Stem Cells

    Researchers investigated the mechanism by which lncRNA LINC00261 affected the biological functions of cancer stem cells during the progression of pancreatic cancer.
    [Cell Death Discovery]

    Full Article

    Adipose-Derived Stem/Stromal Cell Secretome Modulates Breast Cancer Cell Proliferation and Differentiation State towards Aggressiveness

    To understand the role of the adipose-derived stem cell secretome in breast cancer cell proliferation, death, and phenotype alteration, adipose-derived stem cell-conditioned medium was used to cultivate MCF-7 and MDA-MB-231 cells.
    [Biochimie]

    Abstract

    AKT Inhibitor AZD5363 Suppresses Stemness and Promotes Anti-Cancer Activity of 3,3′-Diindolylmethane in Human Breast Cancer Cells

    Investigators observed that proportion of CD133+Nanog+ subpopulation in MCF-7 cells was significantly increased after 3,3′-diindolylmethane administration with up-regulated AKT activity by using CyTOF assay.
    [Toxicology and Applied Pharmacology]

    AbstractGraphical Abstract

    Camalexin, an Indole Phytoalexin, Inhibits Cell Proliferation, Migration, and Mammosphere Formation in Breast Cancer Cells via the Aryl Hydrocarbon Receptor

    The authors found that camalexin inhibited cell proliferation and migration of breast cancer cell lines. Camalexin also suppressed breast cancer stem cell-derived mammosphere formation.
    [Journal of Natural Medicines]

    Abstract
    Request your free copy of the 'Directed Differentiation of Pluripotent Stem Cells' Wallchart
    REVIEWS

    The Plasticity of Pancreatic Cancer Stem Cells: Implications in Therapeutic Resistance

    A better understanding of the molecular and functional landscape of pancreatic cancer (PC) stem cells-intrinsic evasion of chemotherapeutic drugs offers a facile opportunity for treating PC, an intractable cancer with a grim prognosis and in dire need of effective therapeutic advances.
    [Cancer and Metastasis Reviews]

    Full Article

    The Implications of Nitric Oxide Metabolism in the Treatment of Glial Tumors

    The influence of nitric oxide and nitric oxide synthase (NOS) activity on glioma stem cells seem to be of particular importance. The use of specific inhibitors may allow the reduction of tumor growth and its tendency to relapse.
    [Neurochemistry International]

    Abstract
    INDUSTRY AND POLICY NEWS

    HUTCHMED Initiates a Phase Ib/II Trial of Fruquintinib in Combination with Tislelizumab in Advanced Triple Negative Breast Cancer or Advanced Endometrial Cancer

    HUTCHMED initiated a Phase Ib/II study of fruquintinib in combination with BeiGene’s tislelizumab in patients with advanced triple negative breast cancer or advanced endometrial cancer in the US. This trial is to explore the potential for the addition of a highly selective vascular endothelial growth factor receptor inhibitor, fruquintinib, to anti-programmed death-1 antibody tislelizumab in inducing activity to immune checkpoint inhibitors.
    [HUTCHMED]

    Press Release

    Castle Biosciences Awarded US Federal Supply Schedule Contract for DecisionDx-Melanoma

    Castle Biosciences, Inc. announced that it has been awarded a five-year US Federal Supply Schedule contract from the Veterans Health Administration for its DecisionDx®-Melanoma gene expression profile test.
    [Castle Biosciences, Inc.]

    Press Release
    FEATURED EVENT

    Annual London Stem Cell Network Symposium

    October 19, 2021
    London, England, United Kingdom

    > See All Events

    JOB OPPORTUNITIES

    Senior Researcher – Genomic and Epigenetic Changes of Rare Tumors

    St. Jude Children’s Research Hospital – Memphis, Tennessee, United States

    Faculty Positions – Cancer Research

    Sidney Kimmel Cancer Center at Jefferson Health – Philadelphia, Pennsylvania, United States

    Research Associate – Senescence in Lung Tumor

    University of Cambridge – Cambridge, England, United Kingdom

    Postdoctoral Fellow – Normal and Leukemic Hematopoietic Stem Cells

    Indiana University – Indianapolis, Indiana, United States

    Research Fellow – Cancer Immunology and Stem Cells Research

    Dana-Farber Cancer Institute- Boston, Massachusetts, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Cancer Stem Cell News Twitter